



# Viral Factors Important for Efficient Replication of Influenza A Viruses in Cells of the Central Nervous System

Jurre Y. Siegers,<sup>a</sup> Marco W. G. van de Bildt,<sup>a</sup> Zhanmin Lin,<sup>b</sup> Lonneke M. Leijten,<sup>a</sup> Rémon A. M. Lavrijssen,<sup>a</sup> Theo Bestebroer,<sup>a</sup> Monique I. J. Spronken,<sup>a</sup> Chris I. De Zeeuw,<sup>b</sup> Zhenyu Gao,<sup>b</sup> Eefje J. A. Schrauwen,<sup>a\*</sup> Thijs Kuiken,<sup>a</sup> Debby van Riel<sup>a</sup>

<sup>a</sup>Department of Viroscience, Erasmus MC Rotterdam, Rotterdam, the Netherlands

<sup>b</sup>Department of Neuroscience, Erasmus MC Rotterdam, Rotterdam, the Netherlands

**ABSTRACT** Central nervous system (CNS) disease is one of the most common extrapulmonary tract complications of influenza A virus infections. Remarkably, zoonotic H5N1 virus infections are more frequently associated with CNS disease than seasonal or pandemic influenza viruses. Little is known about the interaction between influenza A viruses and cells of the CNS; therefore, it is currently unknown which viral factors are important for efficient replication. Here, we determined the replication kinetics of a seasonal, pandemic, zoonotic, and lab-adapted influenza A virus in human neuron-like (SK-N-SH) and astrocyte-like (U87-MG) cells and primary mouse cortex neurons. In general, highly pathogenic avian influenza (HPAI) H5N1 virus replicated most efficiently in all cells, which was associated with efficient attachment and infection. Seasonal H3N2 and to a lesser extent pandemic H1N1 virus replicated in a trypsin-dependent manner in SK-N-SH but not in U87-MG cells. In the absence of trypsin, only HPAI H5N1 and WSN viruses replicated. Removal of the multibasic cleavage site (MBCS) from HPAI H5N1 virus attenuated, but did not abrogate, replication. Taken together, our results showed that the MBCS and, to a lesser extent, the ability to attach are important determinants for efficient replication of HPAI H5N1 virus in cells of the CNS. This suggests that both an alternative hemagglutinin (HA) cleavage mechanism and preference for  $\alpha$ -2,3-linked sialic acids allowing efficient attachment contribute to the ability of influenza A viruses to replicate efficiently in cells of the CNS. This study further improves our knowledge on potential viral factors important for the neurotropic potential of influenza A viruses.

**IMPORTANCE** Central nervous system (CNS) disease is one of the most common extrapulmonary tract complications of influenza A virus infections, and the frequency and severity differ between seasonal, pandemic, and zoonotic influenza viruses. However, little is known about the interaction of these viruses with cells of the CNS. Differences among seasonal, pandemic, and zoonotic influenza viruses in replication efficacy in CNS cells, *in vitro*, suggest that the presence of an alternative HA cleavage mechanism and ability to attach are important viral factors. Identifying these viral factors and detailed knowledge of the interaction between influenza virus and CNS cells are important to prevent and treat this potentially lethal CNS disease.

**KEYWORDS** CNS disease, H1N1, H3N2, H5N1, influenza A virus, encephalitis, extrapulmonary, pathogenesis, viral replication, virus attachment

One of the most common extrapulmonary complications of influenza virus infection is central nervous system (CNS) disease (1, 2). Clinically, CNS disease can range from mild febrile seizures to severe or even fatal meningoencephalitis (2, 3). Although most studies on influenza virus-associated CNS disease have focused on influenza A viruses, viruses of type B are also able to cause CNS disease. This is, however, less frequently observed (2, 4). Influenza A viruses, hereinafter referred to as influenza virus, have been linked to CNS disease since the 1918 H1N1 pandemic (5, 6), and CNS disease

**Citation** Siegers JY, van de Bildt MWG, Lin Z, Leijten LM, Lavrijssen RAM, Bestebroer T, Spronken MIJ, De Zeeuw CI, Gao Z, Schrauwen EJA, Kuiken T, van Riel D. 2019. Viral factors important for efficient replication of influenza A viruses in cells of the central nervous system. *J Virol* 93:e02273-18. <https://doi.org/10.1128/JVI.02273-18>.

**Editor** Stacey Schultz-Cherry, St. Jude Children's Research Hospital

**Copyright** © 2019 Siegers et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Debby van Riel, [d.vanriel@erasmusmc.nl](mailto:d.vanriel@erasmusmc.nl).

\* Present address: Eefje J. A. Schrauwen, Avans University of Applied Science, Breda, the Netherlands.

**Received** 18 December 2018

**Accepted** 5 March 2019

**Accepted manuscript posted online** 13 March 2019


**Published** 15 May 2019

has been observed during all subsequent pandemics (7–12) as well as during seasonal epidemics, with sporadic detection of influenza virus in the CNS or cerebral spinal fluid (CSF) of humans (13–15). Zoonotic influenza viruses only occasionally infect humans, but when they do, they are frequently associated with severe and systemic disease (1). Highly pathogenic avian influenza (HPAI) H5N1 and H7N9 viruses, two recent zoonotic influenza viruses, are both associated with CNS disease (16–19). The HPAI H5N1 virus is possibly the most neurotropic influenza virus known and has frequently been associated with CNS disease in humans and in other naturally (20–23) and experimentally (24–27) infected mammalian species.

In order to infect, replicate in, and spread throughout the CNS, influenza viruses first have to be able to enter the CNS. Entry of influenza viruses into the CNS can occur via, for example, the olfactory (24, 26–28), trigeminal (6, 27, 29, 30), vagus (29–31), and sympathetic (27, 31) nerves and possibly other cranial nerves. The primary targets of influenza viruses are, however, epithelial cells of the respiratory tract (32), which differ from cells of the CNS. Influenza virus infection starts with attachment of the virus to sialic acids (SA) present on host cells (33). Human and avian influenza viruses attach preferentially to  $\alpha$ -2,6- and  $\alpha$ -2,3-linked SA, respectively, present in the upper and lower respiratory tracts of humans, respectively (33). In cells of the CNS, little is known about SA distribution on the different cells at different anatomical locations. One comparative study using lectin immunohistochemistry suggested that in humans, both  $\alpha$ -2,6 and  $\alpha$ -2,3 SA are present on neurons and glial cells in many different regions, including cerebral cortex, hippocampus, brainstem, and cerebellum (34). In the mouse brain, however, SA distribution is less widespread, and regions with and without detectable SA are infected with influenza viruses (34). In another study, it was found that in human cortex tissue, some neurons only express  $\alpha$ -2,3 SA, oligodendrocytes mainly express  $\alpha$ -2,6 SA, while astrocytes appear to express both receptors (35). Moreover, both  $\alpha$ -2,3 and  $\alpha$ -2,6 SA receptors have been found to be present on human neuroblastoma SK-N-SH and SH-SY5Y and human glioblastoma T98G cell lines (36, 37). Given these differential results as well as the fact that SA usage depends on more than  $\alpha$ -2,3 and  $\alpha$ -2,6 SA linkage, e.g.,  $\alpha$ -2,8 SA linkage (38, 39) or even SA-independent entry of the virus (40), more studies should reveal which viruses are able to attach to cells in the CNS.

In order for progeny viruses to infect new cells, cleavage of the immature surface protein hemagglutinin (HA) into the biologically activated and infectious form is required (41). Influenza viruses that contain a monobasic cleavage site can be cleaved by trypsin-like serine proteases such as human airway trypsin-like protease (HAT), transmembrane serine protease 2 (TMPRSS2), TMPRSS4, or matriptase present in the human respiratory tract (42–44). In the human CNS, expression of HAT in the cerebellum (45) and matriptase mRNA in the frontal and temporal cortices, hippocampus, and cerebellum have been reported (46). Viruses that contain a multibasic cleavage site (MBCS), such as the HPAI H5N1 virus, can be cleaved by ubiquitously expressed subtilisin-like proteases such as furin and PC5/6 (41, 47). This MBCS is an important factor contributing to the ability to spread systemically, including in the CNS. Although extrarespiratory spread of HPAI H5N1 virus depends on the presence of the MBCS in ferrets, insertion of an MBCS into a seasonal H3N2 virus did not result in efficient systemic replication in ferrets, suggesting that more factors are necessary (24, 48). Other viruses that are associated with CNS invasion in mice or ferrets are 1918 H1N1 and A/WSN/33 viruses (6, 49, 50). These viruses do not possess an MBCS but use a different protease-mediated mechanism for HA cleavage, allowing trypsin-independent replication. Taken together, virus receptor specificity, receptor availability on host cells, protease distribution and availability, and HA cleavage mechanism all seem to play important roles in influenza virus infection and cell tropism as well as replication efficiency in the respiratory tract and beyond.

To date, not much is known about the replication efficiency of different influenza viruses, especially seasonal viruses, in cells of the CNS. Thus far, evidence from both *in vivo* and *in vitro* studies suggests that HPAI H5N1 viruses are able to infect and replicate




**FIG 1** In the presence of trypsin, HPAI H5N1 virus replicates most efficiently in SK-N-SH, U87-MG, pmCortex, and MDCK cells. (A to D) Growth kinetics of pH1N1, H3N2, HPAI H5N1, and WSN viruses in SK-N-SH, U87-MG, pmCortex, and MDCK cells (MOI of 0.1) in the presence of trypsin. Data are presented as means  $\pm$  SDs from at least three independent experiments. Two-way analysis of variance (ANOVA) with Dunnett’s multiple-comparison tests for individual viruses against HPAI H5N1 virus. \*,  $P \leq 0.05$ ; \*\*\*,  $P \leq 0.001$ ; \*\*\*\*,  $P \leq 0.0001$ .

in neurons and astrocytes (17, 20–27, 36, 51–54), but a direct comparison of replication efficiency in cells of the CNS between seasonal, zoonotic, and pandemic influenza viruses is currently lacking. Similarly, insights into the roles of attachment, protease availability, and presence of an MBCS on replication efficiency in cells of the CNS for these viruses are lacking. Therefore, we here determined the virus attachment, infectivity, and replication kinetics of a seasonal H3N2, 2009 pandemic H1N1 (pH1N1), HPAI H5N1, and WSN viruses in human neuroblastoma (SK-N-SH), human astrocytoma (U87-MG), primary mouse cortex neurons (pmCortex), and Madin-Darby canine kidney (MDCK) cells. Subsequently, we established the importance of the MBCS for the replication efficiency of HPAI H5N1 virus in cells of the CNS.

**RESULTS**

**HPAI H5N1 virus replicates more efficiently in CNS cells than H3N2 and pH1N1 viruses.** The replication kinetics of pH1N1, H3N2, HPAI H5N1, and WSN viruses were determined in SK-N-SH, U87-MG, pmCortex, and MDCK cells in the presence of trypsin. All viruses replicated efficiently in MDCK cells, where HPAI H5N1 virus and H3N2 virus replicated to higher titers than pH1N1 virus and WSN virus (Fig. 1D). In both SK-N-SH and U87-MG cells, HPAI H5N1 virus replicated to a significantly higher titer ( $\sim 7 \log_{10}$  50% tissue culture infective dose [TCID<sub>50</sub>]/ml) than all other viruses (Fig. 1A and B). In U87-MG and pmCortex cells, only HPAI H5N1 and WSN viruses were able to replicate (Fig. 1B and C). In addition to HPAI H5N1 virus, SK-N-SH cells supported replication of pH1N1, H3N2, and WSN viruses, reaching virus titers of  $\sim 5.7$ ,  $\sim 3.9$ , and  $\sim 3.3$ , respectively (Fig. 1A). Overall, our results show that HPAI H5N1 and WSN viruses replicated in all cells investigated and that H3N2 and pH1N1 viruses replicated less efficiently in SK-N-SH cells and not at all in U87-MG cells and pmCortex cells.

**HPAI H5N1 and WSN viruses infected cells more efficiently than H3N2 and pH1N1 viruses.** To determine whether efficient replication was associated with the ability of the virus to enter and infect host cells, we determined the percentage of infection 8 h postinfection (hpi) (multiplicity of infection [MOI] of 3) in SK-N-SH, U87-MG, and MDCK cells, measured by flow cytometry (Fig. 2). In MDCK cells, pH1N1, HPAI H5N1, and WSN




**FIG 2** HPAI H5N1 and WSN viruses infect cells more efficiently than pH1N1 and H3N2 viruses. Percentages of infection in SK-N-SH, U87-MG, and MDCK cells were determined by FACS 8 hpi with either pH1N1, H3N2, WSN, or HPAI H5N1 virus (MOI of 3). Data are presented as means  $\pm$  SDs from at least three independent experiments. Statistical analysis was performed using the two-way ANOVA with Tukey's multiple-comparison test. \*,  $P \leq 0.05$ ; \*\*\*,  $P \leq 0.001$ ; \*\*\*\*,  $P \leq 0.0001$ .

viruses infected significantly more cells than H3N2 virus. In SK-N-SH and U87-MG cells, HPAI H5N1 and WSN viruses infected significantly more cells than H3N2 or pH1N1 viruses.

**pH1N1 and H3N2 viruses attach less efficiently to SK-N-SH and U87-MG cells than HPAI H5N1 and WSN viruses.** To determine whether there were differences in attachment between the viruses and whether this was associated with the infection percentages, we performed a virus attachment assay. The attachment efficiency was scored as follows: inefficient attachment (0% to 5%), low attachment (6% to 25%), intermediate attachment (26% to 75%), and efficient attachment (>76%). HPAI H5N1 virus attached efficiently (>90%) to all cell lines investigated (Fig. 3). WSN virus attached efficiently (>95%) to SK-N-SH and U87-MG cells and intermediately (70%) to MDCK cells (Fig. 3). Pandemic H1N1 virus attached with intermediate efficiency to SK-N-SH (37%) and MDCK (30%) cells (Fig. 3A, B, and D). Seasonal H3N2 virus attached with low efficiency to SK-N-SH (12%) and intermediate efficiency to MDCK (39%) cells (Fig. 3A, B, and D). Neither pH1N1 nor H3N2 virus attached to U87-MG cells (<2%) (Fig. 3A and C). Overall, these results show that pH1N1 and H3N2 viruses attach less efficiently to SK-N-SH and U87-MG cells than H5N1 and WSN viruses.

**HPAI H5N1 and WSN viruses replicate in the absence of trypsin, but H3N2 and pH1N1 viruses do not.** To test whether efficient replication is dependent on the presence of trypsin, we determined the replication kinetics in the absence of trypsin. Replication of HPAI H5N1 and WSN viruses was not affected by the absence of trypsin (Fig. 4). In the presence of trypsin, H3N2 and pH1N1 viruses replicated efficiently in SK-N-SH cells but not in the absence of trypsin (Fig. 4A). To further understand this finding, we analyzed the presence of specific host cell proteases known to cleave the HA protein of H3N2 and pH1N1 viruses (43). We found that neither SK-N-SH nor U87-MG cells expressed HAT, TMPRSS2, nor TMPRSS4 mRNA, whereas these transcripts were present in human nasal cell (HN) cultures and human bronchial/tracheal epithelial (HBTE) cultures (Fig. 5). These results show that HPAI H5N1 and WSN viruses replicate independently of trypsin and that pH1N1 and H3N2 viruses are dependent on trypsin for replication in SK-N-SH cells.

**The MBCS of HPAI H5N1 virus is important but not solely responsible for replication in SK-N-SH cells.** To determine whether efficient replication of HPAI H5N1 virus in cell culture solely depends on the presence of the MBCS, we generated an H5N1 virus without the MBCS. The replication kinetics of the HPAI H5N1<sup>WT</sup> (wild-type) virus was not affected by the presence or absence of trypsin in all cell lines (Fig. 6A). However, the H5N1 <sup>$\Delta$ MBCS</sup> virus, without trypsin, replicated to a lower titer on each cell line investigated. This phenotype was restored by the addition of trypsin to the culture medium, allowing the virus to replicate to wild-type levels (Fig. 6A). The reduced




**FIG 3** HPAI H5N1 and WSN viruses attach more efficiently to SK-N-SH and U87-MG cells than pH1N1 and H3N2 viruses. Virus attachment of pH1N1, H3N2, HPAI H5N1, and WSN viruses (using 100 hemagglutination units [HAU] units) to SK-N-SH, U87-MG, and MDCK cells. (A) Percentages of cells to which viruses attached. (B to D) Representative histograms of SK-N-SH, U87-MG, and MDCK cells. Dotted lines indicate cell control. Data in panel A are presented as means  $\pm$  SDs from at least three independent experiments. Two-way ANOVA with Tukey's multiple-comparison test. \*\*\*,  $P \leq 0.001$ ; \*\*\*\*,  $P \leq 0.0001$ .

replication efficiency of H5N1 <sup>$\Delta$ MBCS</sup> virus was not explained by the ability of the virus to infect cells, since this was not affected (Fig. 6B). In order to determine if there were multiple rounds of infection and that virus detected in the supernatant was not solely the result of primary infected cells, we investigated the percentage of infection at 8 and 24 hpi with an MOI of 0.1, without trypsin, measured by flow cytometry. We found that HPAI H5N1<sup>WT</sup> virus efficiently replicated in MDCK, SK-N-SH, and U87-MG cells as indicated by the increase of infection percentages (Fig. 6C). In contrast, a significant increase for H5N1 <sup>$\Delta$ MBCS</sup> virus only was observed in MDCK and U87-MG cells. In SK-N-SH cells, no increased infection percentage was observed. These results reveal that the MBCS is important but not solely responsible for efficient replication in MDCK and U87-MG cells in the absence of trypsin.

**DISCUSSION**


Here we show that HPAI H5N1 virus replicates more efficiently in human and mouse neuronal cells than seasonal H3N2 and 2009 pandemic H1N1 viruses. Both the ability to attach efficiently and the presence of an MBCS of HPAI H5N1 virus contributed to efficient replication in cells of the CNS, indicative that these are viral factors that contribute to the neurotropic potential of influenza viruses. This fits with the facts that HPAI H5N1 virus is more frequently associated with CNS disease in humans than seasonal and pandemic viruses (1) and that this virus is also more often detected in




**FIG 4** In the absence of trypsin, HPAI H5N1 virus grows most efficiently in SK-N-SH, U87-MG, MDCK, and pmCortex cells. (A to D) Growth kinetics of pH1N1, H3N2, HPAI H5N1, and WSN viruses in SK-N-SH, U87-MG, MDCK, and pmCortex cells (MOI of 0.1) in the absence of trypsin. Data are presented as means  $\pm$  SDs from at least three independent experiments. Two-way ANOVA with Dunnett's multiple-comparison test against H5N1 virus. \*\*,  $P \leq 0.01$  \*\*\*,  $P \leq 0.001$ ; \*\*\*\*,  $P \leq 0.0001$ .

tissues of the CNS in experimentally inoculated laboratory animals than seasonal and pandemic viruses (17, 20–27, 51, 55–58).

The ability of HPAI H5N1 and WSN viruses to replicate efficiently in cells of the CNS seems to be associated with the ability to attach to and infect host cells efficiently.



**FIG 5** HAT, TMPRSS2, and TMPRSS4 mRNAs are not present in SK-N-SH and U87-MG cells. Presence of three known HA cleaving enzymes: human airway trypsin (HAT), transmembrane serine protease 2 (TMPRSS2), and TMPRSS4. Positive-control cell lines human nasal cells (HN) and human bronchial/tracheal epithelial (HBTE) cells did express HAT, TMPRSS2, and TMPRSS4 mRNA.



**FIG 6** H5N1 virus without an MBCS replicates less efficiently in the absence of trypsin. (A) Replication kinetics of HPAI H5N1<sup>WT</sup> and H5N1<sup>ΔMBCS</sup> viruses in SK-N-SH, U87-MG, and MDCK cells (MOI of 0.1) in the presence or absence of trypsin. Statistical analysis was performed using a two-way ANOVA with Tukey's multiple-comparison test against "H5N1<sup>WT</sup> + trypsin." (B) Percentages of infection in SK-N-SH, U87-MG, and MDCK cells were determined by FACS at 8 hpi with HPAI H5N1<sup>WT</sup> and H5N1<sup>ΔMBCS</sup> viruses (MOI of 3). Statistical analysis was performed using the two-way ANOVA with Bonferroni's multiple-comparison test. (C) Percentages of infection in SK-N-SH, U87-MG, and MDCK cells were determined by FACS at 8 and 24 hpi with HPAI H5N1<sup>WT</sup> and H5N1<sup>ΔMBCS</sup> viruses at an MOI of 0.1 in the absence of trypsin. Statistical analysis was performed using the two-way ANOVA with Bonferroni's multiple-comparison test (8 versus 24 hpi). All data are presented as means ± SDs from at least three independent experiments. \*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.001$ ; \*\*\*\*,  $P \leq 0.0001$ .

Especially, HPAI H5N1 virus which replicated efficiently in SK-N-SH and U87-MG cells, attached to high percentages of cells with high intensity, and infected these cells efficiently. WSN virus attached to and infected high percentages of neuronal cells, which resulted in multiple rounds of infection in all cells, although to lower titers on SK-N-SH and U87-MG cells than observed for HPAI H5N1 virus. The latter could be due to the fact that WSN virus is extensively passaged in suckling mouse brains, thereby adapting to mouse neuronal cells and not human neuronal cells. Seasonal H3N2 viruses replicated in SK-N-SH cells, even in the absence of efficient attachment or infection. Whether this is due to low-affinity binding of H3N2 virus, which cannot be detected by our assays, is unknown, but it does suggest that efficient attachment, as observed for H5N1 and WSN viruses on neuronal cells, is not the only viral factor involved in replication of influenza viruses in cells of the CNS. The lack of replication of H3N2 and pH1N1 viruses in U87-MG cells could be explained by both inefficient attachment and infection.

Efficient replication of influenza viruses in cells of the CNS seems to depend in part on the presence of an MBCS or alternative HA cleaving mechanisms. Studies in ferrets, mice, macaques, and chickens show that introduction or removal of an MBCS has

different outcomes based on the virus backbone and host species (24, 48, 59–61). *In vitro*, in the absence of trypsin, only HPAI H5N1 and WSN viruses were able to replicate, indicating that pH1N1 and H3N2 viruses are not able to circumvent the need for trypsin-like protease for HA cleavage. Removal of the MBCS from HPAI H5N1 virus resulted in attenuated replication in SK-N-SH and U87-MG cells in the absence of trypsin but not in pmCortex cells. Viruses without an MBCS that are associated with replication in cells of the CNS *in vivo*, such as the 1918 H1N1 and WSN viruses, have an alternative HA cleavage mechanism (6, 62). The WSN virus lacks a conserved glycosylation site in the neuraminidase making the virus trypsin independent (63) by using the serine-protease plasmin, which is present in many organ systems besides the respiratory tract (64). The 1918 H1N1 virus grows trypsin independent and neuraminidase dependent in MDCK cells and polarized Calu-3 cells but not in Huh-7 cells (65, 66). Our observation that neither HAT, TMPRSS2, nor TMPRSS4 is found in SK-N-SH and U87-MG cells supports the hypothesis that for efficient replication in cells of the CNS, influenza viruses require alternative HA cleavage, as shown for the HPAI H5N1, WSN, and 1918 H1N1 viruses. However, it must be noted that there is limited knowledge on the expression and accessibility of proteases in tissues other than the respiratory tract.

Previous studies on the replication kinetics of influenza viruses in cells of the CNS revealed some differences, which can in part be explained by the use of different cells, virus isolates, and experimental approaches (36, 54). Replication of HPAI H5N1 viruses in differentiated astrocytic cell lines resulted in efficient replication, similar to our observations. However, in SH-SY5Y cells, a subclone cell line derived from SK-N-SH cells, two HPAI H5N1 viruses did not replicate efficiently. This discrepancy could be due to the relatively high MOI used in this study compared to the low MOI we used and which resulted in efficient replication (36). Furthermore, two pandemic H1N1 viruses did not replicate in the neuronal or astrocytic cell lines, which fits with our observation, in the absence of trypsin (54).

Pandemic H1N1 and seasonal H3N2 viruses are occasionally detected in the CNS or CSF in humans and from experimentally inoculated ferrets and mice, even though pH1N1 and H3N2 viruses only replicated in SK-N-SH cells in the presence of trypsin (11–15, 67–70). However, these viruses are rarely isolated in high titers or detected by immunohistochemistry in the CNS of humans or experimentally inoculated ferrets and mice, indicating that these viruses might be able to enter the CNS but that replication is inefficient. This could be attributed to the limited attachment and infection and lack of an alternative HA cleavage mechanism allowing efficient replication. Previously, we showed that even in the absence of active virus replication, proinflammatory cytokines, such as interleukin 6 (IL-6), IL-8, and tumor necrosis factor alpha (TNF- $\alpha$ ), are induced in the CNS of pH1N1 experimentally inoculated ferrets (71). Future studies should reveal how both efficient and inefficient replication in neuronal cells can trigger local proinflammatory responses, for which HPAI H5N1 and H5N1 <sup>$\Delta$ MBCS</sup> viruses might be a good model.

Taken together, results of our study have shown that the presence of an MBCS and, to a lesser extent, the ability to attach are important determinants for replication of HPAI H5N1 virus in cells of the CNS. This suggests that, at least for replication within the CNS, neurotropic influenza viruses contain an alternative HA cleavage mechanism and prefer  $\alpha$ -2,3-linked sialic acids.

## MATERIALS AND METHODS

**Cells.** Human neuroblastoma (neuron like, SK-N-SH) and human glioblastoma (astrocyte like, U87-MG) cells were purchased from Sigma-Aldrich and maintained in Eagle minimal essential medium (EMEM; Lonza, Breda, the Netherlands) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO, USA), 100 IU/ml penicillin (Lonza, Basel, Switzerland), 100  $\mu$ g/ml streptomycin (Lonza), 2 mM glutamine (Lonza), 1.5 mg/ml sodium bicarbonate (Cambrex, Wiesbaden, Germany), sodium pyruvate (Thermo Fisher Scientific, Waltham, MA, USA) and 1 $\times$  (0.1 mM) nonessential amino acids (MP Biomedicals Europe, Illkirch, France). As a control cell line, we have included Madin-Darby canine kidney (MDCK) cells, since these cells are extensively used for influenza virus propagation. MDCK cells were maintained in EMEM supplemented with 10% FBS, 100 IU/ml penicillin, 100  $\mu$ g/ml streptomycin, 2 mM glutamine, 1.5 mg/ml sodium bicarbonate, 1 mM, 10 mM HEPES (Cambrex), and 1 $\times$  (0.1 mM) nonessential amino acids.



**Viruses.** Five viruses were included in this study, a seasonal H3N2 virus (A/Netherlands/213/2003), pH1N1 virus (A/Netherlands/602/2009), and zoonotic HPAI H5N1 virus (A/Indonesia/5/2005) all isolated from humans. Neurotropic WSN virus (A/WSN/33) and H5N1 virus lacking an MBCS (H5N1<sup>ΔMBCS</sup>) were generated using reverse genetics as described before (72) and passed once on 293T cells and once on MDCK cells. Experiments involving HPAI H5N1 and H5N1<sup>ΔMBCS</sup> viruses were performed under biosafety level 3 conditions.

**Isolation and culture of primary mouse cortex neurons.** Animals were housed and experiments were conducted in strict compliance with European guidelines (EU directive on animal testing 86/609/EEC) and Dutch legislation (Experiments on Animals Act, 1997). Primary mouse cortex tissue was isolated from embryonic day 17 (E17) to E19 C57BL6 mouse embryos (Charles River Laboratories, Wilmington, MA, USA). The cultures were pooled cortexes of several mouse embryos originating from one mother. In brief, the cortex was dissected in ice-cold Hanks' balanced salt solution (HBSS; Life Technologies) supplemented with 20  $\mu\text{g}/\text{ml}$  gentamicin (Life Technologies) under guidance with a stereomicroscope (Nikon). Next, tissues were cut to  $\sim 1 \text{ mm}^3$  using a scalpel and digested using medium consisting of HBSS supplemented with 10 U/ml papain (Sigma), 2.5 U/ml DNase I (Roche), and 4 mM  $\text{MgCl}_2$  (Sigma-Aldrich) at 33°C for 15 min. After incubation, cells were washed once in 1 ml of 10% FBS (Life Technologies) in HBSS to stop the digestion. A second "mechanical digestion" was performed by carefully pipetting up and down in digestion buffer (without papain). After washing in HBSS twice, cells were counted using a Moxi Go cell counter (Orflo, Ketchum, ID, USA) and seeded on laminin (500  $\mu\text{g}/\text{ml}$ ; Sigma)-coated 1.5H 96-well glass-bottomed plates (Cellvis, Sunnyvale, CA, USA) at a density of  $1.0 \times 10^4$  cells/well. For the first 2 h, the cells were cultured in culture medium containing 10% FBS. After 2 h, medium was replaced with fresh culture medium, without FBS. The culture medium contains primary neuron growth medium (PNBM; Lonza), GS-21 supplement (Tebu-Bio, Le-Perray-en-Yvelines, France), 5  $\mu\text{g}/\text{ml}$  gentamicin (Thermo Fisher), and 2 mM GlutaMAX (Life Technologies). Half of the medium was changed once per week, and cells were cultured for 7 to 10 days before use.

**Replication kinetics.** Cells were infected at a multiplicity of infection (MOI) of 0.1. Virus dilutions were prepared in the cell-specific culture medium without serum (infection medium, see "Virus titrations"). After 1 h of virus absorption, cells were washed once with fresh infection medium and cultured in infection medium in the presence or absence of L-1-tosylamide-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin (see "Virus titration"). At time points 1, 6, 24, and 48 h postinfection (hpi), 100  $\mu\text{l}$  supernatant was collected and stored at  $-80^\circ\text{C}$  for subsequent virus titration. All experiments were performed three times (biological replicates), and each experiment was performed with duplicates (technical replicates) from which the average was used for statistical analysis.

**Virus titrations.** The 50% tissue culture infectious dose ( $\text{TCID}_{50}$ ) in cell supernatant was determined by endpoint titration on MDCK cells, as described before (73). Briefly, 10-fold serial dilutions of cell supernatants were prepared in infection medium. Infection medium consisted of EMEM, 100 IU/ml penicillin, 100  $\mu\text{g}/\text{ml}$  streptomycin, 2 mM glutamine, 1.5 mg/ml sodium bicarbonate, 10 mM HEPES,  $1 \times (0.1 \text{ mM})$  nonessential amino acids, and 1  $\mu\text{g}/\mu\text{l}$  TPCK-treated trypsin (Sigma-Aldrich). Before inoculation, MDCK cells were washed twice with phosphate-buffered saline (PBS) to remove remaining FBS. One hundred microliters of the diluted supernatant was used to inoculate a confluent monolayer of MDCK cells in 96-well plates. After 1 h at 37°C, the cells were washed once with infection medium, and 200  $\mu\text{l}$  new infection medium was added to each well. Three days after infection, supernatants of infected cell cultures were tested for agglutinating activity using turkey erythrocytes as an indicator of virus replication. The titers of infectivity were calculated from three replicates according to the method of Kärber (74). An initial 1:10 dilution of supernatant resulted in a detection limit of  $10^{1.5} \text{ TCID}_{50}/\text{ml}$ .

**Percentage of infection.** After 8 hpi (with an MOI of 3) or after 8 and 24 hpi (with an MOI of 0.1), in the absence of trypsin, cells were collected, fixed, and permeabilized using BD Cytofix/Cytoperm solution (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer's instructions. Cells were incubated with 2% normal goat serum (NGS; Dako, Denmark) in PBS for 10 min on ice. Next, influenza A virus was detected using a monoclonal antibody against influenza A virus nucleoprotein (clone HB-65, 1  $\mu\text{g}/\text{ml}$ ; ATCC) or mouse IgG2a isotype control (MAB003, 1  $\mu\text{g}/\text{ml}$ ; Dako) in BD Perm/Wash containing 2% NGS and incubated for 1 h on ice and in the dark. Cells were washed twice and incubated with goat anti-mouse IgG2a conjugated to Alexa Fluor 488 (8  $\mu\text{g}/\text{ml}$ ; Life Technologies, Inc., the Netherlands) for 1 h in the dark and on ice. After incubation, cells were washed twice and resuspended in fluorescence-activated cell sorting (FACS) buffer. Cells were measured and data collected using a BD FACSCanto II (BD Biosciences, USA). Data were analyzed using FlowJo 10 software (Ashland, OR, USA). All experiments were performed three times (biological replicates), and each experiment included duplicate (technical replicate) measurements from which the average was calculated and used for further analysis.

**Virus attachment.** For influenza virus histochemistry, viruses were grown, inactivated, and labeled as described previously (32). As a control, uninfected MDCK cells and cell debris were harvested and processed similarly. Subsequently, in a 12-well plate,  $2 \times 10^5$  cells were seeded, and 1 day later, the near confluent monolayers of MDCK, SK-N-SH, and U87-MG cells were harvested, washed in FACS buffer, and incubated with fluorescein isothiocyanate (FITC)-labeled virus for 1 h at 4°C. After incubation, the cells were washed twice in FACS buffer and measured using a BD FACSCanto II (BD Biosciences, USA). Data were analyzed using FlowJo 10 software (Ashland, OR, USA). All experiments were performed three times (biological replicates), and each experiment was performed with duplicates (technical replicates) from which the average was used for statistical analysis.

**PCR proteases.** Since MDCK cells are of canine origin, we have included primary human nasal (HN) cells (MucilAir, pool of 14 donors; Epithelix, Geneva, Switzerland), and primary human bronchial/tracheal epithelial cells (HBTE) (catalog number CC-2540, lot 97366, donor 97366: male, Caucasian, 57 years,

healthy; Lonza) as control cell types for the expression of human HAT, human TMPRSS2, and human TMPRSS4. Total RNA was isolated from SK-N-SH, U87-MG, HN, and HBTE cells using the High Pure RNA isolation kit (Roche, Basel, Switzerland) according to the manufacturer's protocol. cDNA synthesis was performed using oligo(dT) primers and Superscript IV (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. For detection of HAT-, TMPRSS2-, and TMPRSS4-specific mRNAs, primers were used from Böttcher-Friebertshäuser et al. (75). The GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA was detected using primers GAPDH-FW (5'-TGA ACG GGA AGC TCA CTG G-3') and GAPDH-RV (5'-TCC ACC ACC CTG TTG CTG TA-3') as a control for sample quality. PCR products were resolved on a 1.5% agarose gel stained with SYBR Safe (Thermo Fisher) and imaged using a ChemiDoc MP imaging system and ImageLab 5.1 (Bio-Rad, Hercules, CA, USA). To confirm the specificity of the primers, PCR products were extracted from the gel and sequenced using a BigDye Terminator v3.1 Cycle sequencing kit (Applied Biosystems) and a 3130XL genetic analyzer (Applied Biosystems), according to the instructions of the manufacturer.

**Statistical analysis.** Statistical analyses were performed using GraphPad Prism 6.0h software (La Jolla, CA, USA) for Mac. Each specific test is indicated in the figure legends. *P* values of  $\leq 0.05$  were considered significant. All data are presented as means  $\pm$  standard deviations (SDs) from at least three independent experiments.

## ACKNOWLEDGMENTS

We thank Mathilde Richard for providing the human nasal cells and Laurine Rijsbergen for providing human bronchial/tracheal epithelial cells.

This work was supported by a fellowship from the Netherlands Organization for Scientific Research (contract 91614115 and 91718308), the Erasmus MC Foundation, and an ESCMID research grant.

## REFERENCES

- Kuiken T, Taubenberger JK. 2008. Pathology of human influenza revisited. *Vaccine* 26:D59–D66. <https://doi.org/10.1016/j.vaccine.2008.07.025>.
- Sellers SA, Hagan RS, Hayden FG, Fischer WA, II. 2017. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. *Influenza Other Respir Viruses* 11:372–393. <https://doi.org/10.1111/irv.12470>.
- Toovey S. 2008. Influenza-associated central nervous system dysfunction: a literature review. *Travel Med Infect Dis* 6:114–124. <https://doi.org/10.1016/j.tmaid.2008.03.003>.
- Popescu CP, Florescu SA, Lupulescu E, Zaharia M, Tardei G, Lazar M, Ceausu E, Ruta SM. 2017. Neurologic complications of influenza B virus infection in adults, Romania. *Emerg Infect Dis* 23:574–581. <https://doi.org/10.3201/eid2304.161317>.
- Maurizi CP. 2010. Influenza caused epidemic encephalitis (encephalitis lethargica): the circumstantial evidence and a challenge to the nonbelievers. *Med Hypotheses* 74:798–801. <https://doi.org/10.1016/j.mehy.2009.12.012>.
- de Wit E, Siegiers J, Cronin JM, Weatherman S, van den Brand J, Leijten LM, van Run P, Begeman L, van den Ham HJ, Andeweg AC, Bushmaker T, Scott DP, Saturday G, Munster VJ, Feldmann H, van Riel D. 2018. 1918 H1N1 influenza virus replicates and induces pro-inflammatory cytokine responses in extrapulmonary tissues of ferrets. *J Infect Dis* 217:1237–1246. <https://doi.org/10.1093/infdis/jiy003>.
- Flewett TH, Hoult JG. 1958. Influenzal encephalopathy and postinfluenzal encephalitis. *Lancet* 2:11–15.
- McConkey CB, Daws RA. 1958. Neurological disorders associated with Asian influenza. *Lancet* 2:15–17. [https://doi.org/10.1016/S0140-6736\(58\)90004-7](https://doi.org/10.1016/S0140-6736(58)90004-7).
- Wells CE. 1971. Neurological complications of so-called "influenza". A winter study in South-east Wales. *Br Med J* 1:369–373. <https://doi.org/10.1136/bmj.1.5745.369>.
- Thraenhart O, Schley G, Kuwert E. 1975. Isolation of influenza virus "A/Hong Kong/1/68 (H3N2)" from liquor cerebrospinalis of patients with CNS involvement (author's transl). *Med Klin* 70:1910–1914. (In German.)
- Khandaker G, Zurynski Y, Buttery J, Marshall H, Richmond PC, Dale RC, Royle J, Gold M, Snelling T, Whitehead B, Jones C, Heron L, McCaskill M, Macartney K, Elliott EJ, Booy R. 2012. Neurologic complications of influenza A(H1N1)pdm09: surveillance in 6 pediatric hospitals. *Neurology* 79:1474–1481. <https://doi.org/10.1212/WNL.0b013e31826d5ea7>.
- Simon M, Henu R, Cour M, Casalegno JS, Lina B, Argaud L. 2013. Fatal influenza A(H1N1)pdm09 encephalopathy in immunocompetent man. *Emerg Infect Dis* 19:1005–1007. <https://doi.org/10.3201/eid1906.130062>.
- van Riel D, Leijten LM, Verdijk RM, GeurtsvanKessel C, van der Vries E, van Rossum AM, Osterhaus AD, Kuiken T. 2014. Evidence for influenza virus CNS invasion along the olfactory route in an immunocompromised infant. *J Infect Dis* 210:419–423. <https://doi.org/10.1093/infdis/jiu097>.
- Fujimoto S, Kobayashi M, Uemura O, Iwasa M, Ando T, Katoh T, Nakamura C, Maki N, Togari H, Wada Y. 1998. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. *Lancet* 352:873–875. [https://doi.org/10.1016/S0140-6736\(98\)12449-2](https://doi.org/10.1016/S0140-6736(98)12449-2).
- Fernandez-Blazquez A, Castanon-Apilanez M, Alvarez-Arguelles ME, Sabater-Cabrera C, Rojo-Alba S, Boga JA, de la Tassa GM, Quindos Fernandez B, Melon S. 5 November 2018. Neuroinvasion of influenza A/H3N2: a fatal case in an immunocompetent adult. *J Neurovirol* <https://doi.org/10.1007/s13365-018-0690-9>.
- Gu J, Xie Z, Gao Z, Liu J, Korteweg C, Ye J, Lau LT, Lu J, Gao Z, Zhang B, McNutt MA, Lu M, Anderson VM, Gong E, Yu AC, Lipkin WI. 2007. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. *Lancet* 370:1137–1145. [https://doi.org/10.1016/S0140-6736\(07\)61515-3](https://doi.org/10.1016/S0140-6736(07)61515-3).
- de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, Beld M, Le TP, Truong HK, Nguyen VV, Tran TH, Do QH, Farrar J. 2005. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. *N Engl J Med* 352:686–691. <https://doi.org/10.1056/NEJMoa044307>.
- Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Li X, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Zhang Y, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. *N Engl J Med* 368:1888–1897. <https://doi.org/10.1056/NEJMoa1304459>.
- Uyeki TM, Katz JM, Jernigan DB. 2017. Novel influenza A viruses and pandemic threats. *Lancet* 389:2172–2174. [https://doi.org/10.1016/S0140-6736\(17\)31274-6](https://doi.org/10.1016/S0140-6736(17)31274-6).
- Thanawongnuwech R, Amonsin A, Tantilertcharoen R, Damrongwatanapokin S, Theamboonlers A, Payungporn S, Nanthapornphiphat K, Ratanamunghaklan S, Tunak E, Songserm T, Vivatthanavanich V, Lekdumrongsak T, Kesdangakonwut S, Tunhikorn S, Poovorawan Y. 2005. Probable tiger-to-tiger transmission of avian influenza H5N1. *Emerg Infect Dis* 11:699–701. <https://doi.org/10.3201/eid1105.050007>.
- Keawcharoen J, Oraveerakul K, Kuiken T, Fouchier RA, Amonsin A, Payungporn S, Noppornpanth S, Wattanonorn S, Theamboonlers A, Tantilertcharoen R, Pattanarangsarn R, Arya N, Ratanakorn P, Osterhaus DM, Poovorawan Y. 2004. Avian influenza H5N1 in tigers and leopards. *Emerg Infect Dis* 10:2189–2191. <https://doi.org/10.3201/eid1012.040759>.
- Rimmelzwaan GF, van Riel D, Baars M, Bestebroer TM, van Amerongen G, Fouchier RA, Osterhaus AD, Kuiken T. 2006. Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of

- virus spread within and between hosts. *Am J Pathol* 168:176–183. <https://doi.org/10.2353/ajpath.2006.050466>.
23. Klopffleisch R, Wolf PU, Wolf C, Harder T, Starick E, Niebuhr M, Mettenleiter TC, Teifke JP. 2007. Encephalitis in a stone marten (*Martes foina*) after natural infection with highly pathogenic avian influenza virus subtype H5N1. *J Comp Pathol* 137:155–159. <https://doi.org/10.1016/j.jcpa.2007.06.001>.
  24. Schrauwen EJ, Herfst S, Leijten LM, van Run P, Bestebroer TM, Linster M, Bodewes R, Kreijtz JH, Rimmelzwaan GF, Osterhaus AD, Fouchier RA, Kuiken T, van Riel D. 2012. The multibasic cleavage site in H5N1 virus is critical for systemic spread along the olfactory and hematogenous routes in ferrets. *J Virol* 86:3975–3984. <https://doi.org/10.1128/JVI.06828-11>.
  25. Shinya K, Makino A, Hatta M, Watanabe S, Kim JH, Hatta Y, Gao P, Ozawa M, Le QM, Kawaoka Y. 2011. Subclinical brain injury caused by H5N1 influenza virus infection. *J Virol* 85:5202–5207. <https://doi.org/10.1128/JVI.00239-11>.
  26. Bodewes R, Kreijtz JH, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzwaan GF, Kuiken T. 2011. Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation. *Am J Pathol* 179:30–36. <https://doi.org/10.1016/j.ajpath.2011.03.026>.
  27. Park CH, Ishinaka M, Takada A, Kida H, Kimura T, Ochiai K, Umemura T. 2002. The invasion routes of neurovirulent A/Hong Kong/483/97 (H5N1) influenza virus into the central nervous system after respiratory infection in mice. *Arch Virol* 147:1425–1436. <https://doi.org/10.1007/s00705-001-0750-x>.
  28. Yamada M, Bingham J, Payne J, Rookes J, Lowther S, Haining J, Robinson R, Johnson D, Middleton D. 2012. Multiple routes of invasion of wild-type clade 1 highly pathogenic avian influenza H5N1 virus into the central nervous system (CNS) after intranasal exposure in ferrets. *Acta Neuropathol* 124:505–516. <https://doi.org/10.1007/s00401-012-1010-8>.
  29. Shinya K, Shimada A, Ito T, Otsuki K, Morita T, Tanaka H, Takada A, Kida H, Umemura T. 2000. Avian influenza virus intranasally inoculated infects the central nervous system of mice through the general visceral afferent nerve. *Arch Virol* 145:187–195. <https://doi.org/10.1007/s007050050016>.
  30. Tanaka H, Park CH, Ninomiya A, Ozaki H, Takada A, Umemura T, Kida H. 2003. Neurotropism of the 1997 Hong Kong H5N1 influenza virus in mice. *Vet Microbiol* 95:1–13. [https://doi.org/10.1016/S0378-1135\(03\)00132-9](https://doi.org/10.1016/S0378-1135(03)00132-9).
  31. Matsuda K, Park CH, Sunden Y, Kimura T, Ochiai K, Kida H, Umemura T. 2004. The vagus nerve is one route of transneuronal invasion for intranasally inoculated influenza A virus in mice. *Vet Pathol* 41:101–107. <https://doi.org/10.1354/vp.41-2-101>.
  32. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. 2007. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. *Am J Pathol* 171:1215–1223. <https://doi.org/10.2353/ajpath.2007.070248>.
  33. Imai M, Kawaoka Y. 2012. The role of receptor binding specificity in interspecies transmission of influenza viruses. *Curr Opin Virol* 2:160–167. <https://doi.org/10.1016/j.coviro.2012.03.003>.
  34. Kim M, Yu JE, Lee JH, Chang BJ, Song CS, Lee B, Paik DJ, Nahm SS. 2013. Comparative analyses of influenza virus receptor distribution in the human and mouse brains. *J Chem Neuroanat* 52:49–57. <https://doi.org/10.1016/j.jchemneu.2013.05.002>.
  35. Eash S, Tavares R, Stopa EG, Robbins SH, Brossay L, Atwood WJ. 2004. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. *Am J Pathol* 164:419–428. [https://doi.org/10.1016/S0002-9440\(10\)63132-X](https://doi.org/10.1016/S0002-9440(10)63132-X).
  36. Ng YP, Lee SM, Cheung TK, Nicholls JM, Peiris JS, Ip NY. 2010. Avian influenza H5N1 virus induces cytopathy and proinflammatory cytokine responses in human astrocytic and neuronal cell lines. *Neuroscience* 168:613–623. <https://doi.org/10.1016/j.neuroscience.2010.04.013>.
  37. Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF. 2012. Cell surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and neuroblastoma cells. *BMC Microbiol* 12:162. <https://doi.org/10.1186/1471-2180-12-162>.
  38. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, Paulson JC, Wilson IA. 2006. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. *J Mol Biol* 355:1143–1155. <https://doi.org/10.1016/j.jmb.2005.11.002>.
  39. Wu W, Air GM. 2004. Binding of influenza viruses to sialic acids: reasortant viruses with A/NWS/33 hemagglutinin bind to alpha2,8-linked sialic acid. *Virology* 325:340–350. <https://doi.org/10.1016/j.virol.2004.05.013>.
  40. Londrigan SL, Tate MD, Brooks AG, Reading PC. 2012. Cell-surface receptors on macrophages and dendritic cells for attachment and entry of influenza virus. *J Leukoc Biol* 92:97–106. <https://doi.org/10.1189/jlb.1011492>.
  41. Bertram S, Glowacka I, Steffen I, Kuhl A, Pohlmann S. 2010. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. *Rev Med Virol* 20:298–310. <https://doi.org/10.1002/rmv.657>.
  42. Schrauwen EJ, de Graaf M, Herfst S, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2014. Determinants of virulence of influenza A virus. *Eur J Clin Microbiol Infect Dis* 33:479–490. <https://doi.org/10.1007/s10096-013-1984-8>.
  43. Garten W, Braden C, Arendt A, Peitsch C, Baron J, Lu Y, Pawletko K, Hards K, Steinmetzer T, Böttcher-Friebertshäuser E. 2015. Influenza virus activating host proteases: identification, localization and inhibitors as potential therapeutics. *Eur J Cell Biol* 94:375–383. <https://doi.org/10.1016/j.ejcb.2015.05.013>.
  44. Böttcher-Friebertshäuser E, Klenk HD, Garten W. 2013. Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium. *Pathog Dis* 69:87–100. <https://doi.org/10.1111/2049-632X.12053>.
  45. Hahner S, Fassnacht M, Hammer F, Schammann M, Weismann D, Hansen IA, Allolio B. 2005. Evidence against a role of human airway trypsin-like protease—the human analogue of the growth-promoting rat adrenal secretory protease—in adrenal tumorigenesis. *Eur J Endocrinol* 152:143–153. <https://doi.org/10.1530/eje.1.01834>.
  46. Lanhech E, Desilets A, Beliveau F, Flamier A, Mahmoud S, Bernier G, Gris D, Leduc R, Lavoie C. 2017. The type II transmembrane serine protease matriptase cleaves the amyloid precursor protein and reduces its processing to beta-amyloid peptide. *J Biol Chem* 292:20669–20682. <https://doi.org/10.1074/jbc.M117.792911>.
  47. Stieneke-Grober A, Vey M, Angliker H, Shaw E, Thomas G, Roberts C, Klenk HD, Garten W. 1992. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. *EMBO J* 11:2407–2414. <https://doi.org/10.1002/j.1460-2075.1992.tb05305.x>.
  48. Schrauwen EJ, Bestebroer TM, Munster VJ, de Wit E, Herfst S, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2011. Insertion of a multibasic cleavage site in the haemagglutinin of human influenza H3N2 virus does not increase pathogenicity in ferrets. *J Gen Virol* 92:1410–1415. <https://doi.org/10.1099/vir.0.030379-0>.
  49. Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H. 1995. The substantia nigra is a major target for neurovirulent influenza A virus. *J Exp Med* 181:2161–2169. <https://doi.org/10.1084/jem.181.6.2161>.
  50. Aronsson F, Robertson B, Ljunggren HG, Kristensson K. 2003. Invasion and persistence of the neuroadapted influenza virus A/WSN/33 in the mouse olfactory system. *Viral Immunol* 16:415–423. <https://doi.org/10.1089/0882240322396208>.
  51. Mak GCK, Kwan MY, Mok CKP, Lo JYC, Peiris M, Leung CW. 2018. Influenza A(H5N1) virus infection in a child with encephalitis complicated by obstructive hydrocephalus. *Clin Infect Dis* 66:136–139. <https://doi.org/10.1093/cid/cix707>.
  52. Pringproa K, Rungsiwivut R, Tantilertcharoen R, Praphet R, Pruksananonda K, Baumgartner W, Thanawongnuwech R. 2015. Tropism and induction of cytokines in human embryonic-stem cells-derived neural progenitors upon inoculation with highly- pathogenic avian H5N1 influenza virus. *PLoS One* 10:e0135850. <https://doi.org/10.1371/journal.pone.0135850>.
  53. Lin X, Wang R, Zhang J, Sun X, Zou Z, Wang S, Jin M. 2015. Insights into human astrocyte response to H5N1 infection by microarray analysis. *Viruses* 7:2618–2640. <https://doi.org/10.3390/v7052618>.
  54. Ng YP, Yip TF, Peiris JSM, Ip NY, Lee S. 2018. Avian influenza A H7N9 virus infects human astrocytes and neuronal cells and induces inflammatory immune responses. *J Neurovirol* 24:752–760. <https://doi.org/10.1007/s13365-018-0659-8>.
  55. Zhang Z, Zhang J, Huang K, Li KS, Yuen KY, Guan Y, Chen H, Ng WF. 2009. Systemic infection of avian influenza A virus H5N1 subtype in humans. *Hum Pathol* 40:735–739. <https://doi.org/10.1016/j.humpath.2008.08.015>.
  56. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. 2002. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. *J Virol* 76:4420–4429. <https://doi.org/10.1128/JVI.76.9.4420-4429.2002>.
  57. Lipatov AS, Krauss S, Guan Y, Peiris M, Rehng JE, Perez DR, Webster RG. 2003. Neurovirulence in mice of H5N1 influenza virus genotypes isolated

- from Hong Kong poultry in 2001. *J Virol* 77:3816–3823. <https://doi.org/10.1128/JVI.77.6.3816-3823.2003>.
58. Iwasaki T, Itamura S, Nishimura H, Sato Y, Tashiro M, Hashikawa T, Kurata T. 2004. Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation. *Acta Neuropathol* 108:485–492. <https://doi.org/10.1007/s00401-004-0909-0>.
  59. Hatta M, Gao P, Halfmann P, Kawaoka Y. 2001. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. *Science* 293:1840–1842. <https://doi.org/10.1126/science.1062882>.
  60. Munster VJ, Schrauwen EJ, de Wit E, van den Brand JM, Bestebroer TM, Herfst S, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2010. Insertion of a multibasic cleavage motif into the hemagglutinin of a low-pathogenic avian influenza H6N1 virus induces a highly pathogenic phenotype. *J Virol* 84:7953–7960. <https://doi.org/10.1128/JVI.00449-10>.
  61. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. 2001. Pathogenesis of influenza A (H5N1) virus infection in a primate model. *J Virol* 75:6687–6691. <https://doi.org/10.1128/JVI.75.14.6687-6691.2001>.
  62. Tesoriero C, Codita A, Zhang MD, Cherninsky A, Karlsson H, Grassi-Zucconi G, Bertini G, Harkany T, Ljungberg K, Lijestrom P, Hokfelt TG, Bentivoglio M, Kristensson K. 2016. H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice. *Proc Natl Acad Sci U S A* 113:E368–E377. <https://doi.org/10.1073/pnas.1521463112>.
  63. Li S, Schulman J, Itamura S, Palese P. 1993. Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. *J Virol* 67:6667–6673.
  64. Goto H, Wells K, Takada A, Kawaoka Y. 2001. Plasminogen-binding activity of neuraminidase determines the pathogenicity of influenza A virus. *J Virol* 75:9297–9301. <https://doi.org/10.1128/JVI.75.19.9297-9301.2001>.
  65. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swaine DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, Garcia-Sastre A. 2005. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. *Science* 310:77–80. <https://doi.org/10.1126/science.1119392>.
  66. Chaipan C, Kobasa D, Bertram S, Glowacka I, Steffen I, Tsegaye TS, Takeda M, Bugge TH, Kim S, Park Y, Marzi A, Pohlmann S. 2009. Proteolytic activation of the 1918 influenza virus hemagglutinin. *J Virol* 83:3200–3211. <https://doi.org/10.1128/JVI.02205-08>.
  67. Santini M, Kutlesa M, Zarkovic K, Drazenovic V, Barsic B. 2012. Influenza A 2009 H1N1 encephalitis in adults with viral RNA in cerebrospinal fluid. *Scand J Infect Dis* 44:992–996. <https://doi.org/10.3109/00365548.2012.689849>.
  68. van den Brand JM, Stittelaar KJ, van Amerongen G, Reperant L, de Waal L, Osterhaus AD, Kuiken T. 2012. Comparison of temporal and spatial dynamics of seasonal H3N2, pandemic H1N1 and highly pathogenic avian influenza H5N1 virus infections in ferrets. *PLoS One* 7:e42343. <https://doi.org/10.1371/journal.pone.0042343>.
  69. Min JY, Chen GL, Santos C, Lamirande EW, Matsuoka Y, Subbarao K. 2010. Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. *Virology* 408:128–133. <https://doi.org/10.1016/j.virol.2010.09.009>.
  70. Hosseini S, Wilk E, Michaelsen-Preusse K, Gerhauser I, Baumgartner W, Geffers R, Schughart K, Korte M. 2018. Long-term neuroinflammation induced by influenza A virus infection and the impact on hippocampal neuron morphology and function. *J Neurosci* 38:3060–3080. <https://doi.org/10.1523/JNEUROSCI.1740-17.2018>.
  71. Short KR, Veeris R, Leijten LM, van den Brand JM, Jong VL, Stittelaar K, Osterhaus A, Andeweg A, van Riel D. 2017. Proinflammatory cytokine responses in extra-respiratory tissues during severe influenza. *J Infect Dis* 216:829–833. <https://doi.org/10.1093/infdis/jix281>.
  72. de Wit E, Spronken MI, Vervaeke G, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2007. A reverse-genetics system for influenza A virus using T7 RNA polymerase. *J Gen Virol* 88:1281–1287. <https://doi.org/10.1099/vir.0.82452-0>.
  73. Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. *J Virol Methods* 74:57–66. [https://doi.org/10.1016/S0166-0934\(98\)00071-8](https://doi.org/10.1016/S0166-0934(98)00071-8).
  74. Kärber G. 1931. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. *Naunyn Schmiedebergs Arch Exp Pathol Pharmacol* 162:480–483. <https://doi.org/10.1007/BF01863914>.
  75. Böttcher-Friebertshäuser E, Stein DA, Klenk HD, Garten W. 2011. Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. *J Virol* 85:1554–1562. <https://doi.org/10.1128/JVI.01294-10>.